The Cigna Group

Quarterly Financial Supplement
June 30, 2026

The Cigna Group
June 30, 2026 Quarterly Financial Supplement
Table of Contents

BASIS OF PRESENTATION:

All dollar amounts are in millions, unless otherwise noted.

The Cigna Group® (the "Company" or "our") measures its financial results on a consolidated basis using adjusted income from operations and adjusted revenues. Adjusted income from operations and adjusted revenues on a consolidated basis are not determined in accordance with accounting principles generally accepted in the United States of America ("GAAP") and should not be viewed as a substitute for the most directly comparable GAAP measures which are shareholders' net income and total revenues. The Company also uses adjusted income (loss) from operations to measure the results of its segments, however the segment metric is determined before income taxes.

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group's management because it presents the underlying results of operations of the Company's businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders' net income. The Company defines adjusted income (loss) from operations as shareholders' net income (or income (loss) before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders' net income. See the Financial Highlights page for a reconciliation of consolidated adjusted income from operations to shareholders' net income.

Adjusted revenues is used by The Cigna Group's management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See the Financial Highlights page for a reconciliation of consolidated adjusted revenues to total revenues.

In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

In some financial tables in this Quarterly Financial Supplement, we present percentage changes. When those changes are so large as to become not meaningful, we present "N/M" in place of the computed percentage.

The Cigna Group
Financial Highlights (unaudited)

(Dollars in millions, except per share amounts)	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	% Change	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025	% Change
Total revenues	$ 71,668	$ 67,178	7 %	$ 140,162	$ 132,680	6 %
Net investment results from certain equity method investments	(110)	(44)	150	(87)	(94)	(7)
Adjusted revenues	$ 71,558	$ 67,134	7 %	$ 140,075	$ 132,586	6 %
Shareholders' net income	$ 1,660	$ 1,532	8 %	$ 3,314	$ 2,855	16 %
Pre-Tax Adjusted Income (Loss) From Operations by Segment						
Evernorth Health Services	$ 1,663	$ 1,696	(2) %	$ 3,129	$ 3,130	— %
Cigna Healthcare	1,276	1,094	17	2,790	2,381	17
Corporate and Other Operations	(389)	(357)	9	(766)	(768)	—
Adjusted income tax expense	(496)	(503)	(1)	(1,041)	(973)	7
Consolidated after-tax adjusted income from operations	$ 2,054	$ 1,930	6 %	$ 4,112	$ 3,770	9 %
Adjusted EBITDA (1)	$ 3,172	$ 3,030	5 %	$ 6,392	$ 5,954	7 %
Operating cash flow (see page 11)	$ (421)	$ (1,886)	(78) %	$ 710	$ 34	N/M %
SG&A expense ratio (2)	4.8 %	5.1 %	(30) bps	5.1 %	5.8 %	(70) bps
Adjusted SG&A expense ratio (2)	4.6 %	4.9 %	(30) bps	4.7 %	5.3 %	(60) bps
Weighted average shares (in thousands)	263,962	268,154		263,990	270,540	

	Three Months Ended June 30,					Six Months Ended June 30,				
	2026		2025			2026		2025		
	Pre-tax	After-tax	Pre-tax	After-tax	% Change	Pre-tax	After-tax	Pre-tax	After-tax	% Change
Diluted earnings per share										
Shareholders' net income		$ 6.29		$ 5.71	10 %		$ 12.55		$ 10.55	19 %
Adjustments to reconcile to adjusted income from operations										
Net investment (gains) (3)	$ (0.16)	(0.21)	$ (0.36)	(0.38)		$ (1.05)	(1.09)	$ (0.53)	(0.56)	
Amortization of acquired intangible assets	1.48	1.12	1.57	1.23		2.96	2.32	3.12	2.47	
Special items										
Strategic optimization program	0.27	0.20	0.48	0.37		1.70	1.29	1.27	0.97	
Integration and transaction-related costs	0.13	0.10	0.28	0.21		0.26	0.20	1.07	0.81	
Charges associated with litigation matters	0.28	0.23	—	—		0.25	0.20	—	—	
Deferred tax expenses, net	—	0.06	—	0.06		—	0.13	—	0.13	
(Gain) on sale of businesses	(0.02)	(0.01)	—	—		(0.02)	(0.02)	(0.15)	(0.43)	
Total special items	$ 0.66	0.58	$ 0.76	0.64		$ 2.19	1.80	$ 2.19	1.48	
Adjusted income from operations		$ 7.78		$ 7.20	8 %		$ 15.58		$ 13.94	12 %

CUSTOMER RELATIONSHIPS *(Relationships and lives in thousands)*	As of June 30, 2026	As of June 30, 2025	% Change	As of December 31, 2025	% Change
Pharmacy	118,243	121,892	(3) %	123,603	(4) %
Medical (see page 7)	18,413	18,046	2	18,118	2
Behavioral Care	27,621	23,852	16	28,269	(2)
Dental	18,488	18,446	—	18,438	—
Total customer relationships	182,765	182,236	— %	188,428	(3) %

(1) Adjusted income from operations excluding interest, taxes, depreciation and amortization ("Adjusted EBITDA") is a non-GAAP measure, defined as shareholders' net income excluding income taxes and the pre-tax impact of special items, interest expense, total depreciation and amortization, and net investment results.

(2) SG&A expense ratio is calculated as selling, general and administrative expenses including special items divided by total revenues. Adjusted SG&A expense ratio is calculated as selling, general and administrative expenses excluding special items divided by adjusted revenues.

(3) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

The Cigna Group
Consolidated Income Statements (unaudited)

(Dollars in millions)	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	% Change	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025	% Change
Revenues						
Pharmacy revenues	$ 57,172	$ 53,649	7 %	$ 111,209	$ 102,282	9 %
Premiums	9,859	9,156	8	19,671	21,892	(10)
Fees and other revenues	4,365	4,137	6	8,808	8,032	10
Net investment income	272	236	15	474	474	—
Total revenues	71,668	67,178	7	140,162	132,680	6
Benefits and expenses						
Pharmacy and other service costs	56,703	53,268	6	110,803	101,666	9
Medical costs and other benefit expenses	8,430	7,749	9	16,354	18,247	(10)
Selling, general and administrative expenses excluding special items	3,290	3,271	1	6,611	7,070	(6)
Amortization of acquired intangible assets	389	422	(8)	779	844	(8)
Special items	180	162	11	581	576	1
Total benefits and expenses	68,992	64,872	6	135,128	128,403	5
Income from operations	2,676	2,306	16	5,034	4,277	18
Interest expense and other	(356)	(337)	6	(713)	(699)	2
Gain on sale of businesses	6	—	N/M	17	41	(59)
Net investment (losses) gains	(69)	52	N/M	189	50	278
Income before income taxes	2,257	2,021	12	4,527	3,669	23
Total income taxes	382	389	(2)	791	628	26
Net income	1,875	1,632	15	3,736	3,041	23
Less: Net income attributable to noncontrolling interests	215	100	115	422	186	127
Shareholders' net income	$ 1,660	$ 1,532	8 %	$ 3,314	$ 2,855	16 %

	Three Months Ended June 30,					Six Months Ended June 30,				
	2026		2025			2026		2025		
	Pre-tax	After-tax	Pre-tax	After-tax	% Change	Pre-tax	After-tax	Pre-tax	After-tax	% Change
Shareholders' net income		$ 1,660		$ 1,532	8 %		$ 3,314		$ 2,855	16 %
Adjustments to reconcile to adjusted income from operations										
Net investment (gains) [(1)]	$ (41)	(55)	$ (96)	(103)		$ (276)	(288)	$ (144)	(151)	
Amortization of acquired intangible assets	389	296	422	330		779	611	844	666	
Special items										
Strategic optimization program	70	53	129	98		450	343	344	261	
Integration and transaction-related costs	34	26	74	56		69	53	290	220	
Charges associated with litigation matters	77	60	—	—		66	52	—	—	
Deferred tax expenses, net	—	17	—	17		—	33	—	34	
(Gain) on sale of businesses	(6)	(3)	—	—		(6)	(6)	(41)	(115)	
Adjusted income from operations		$ 2,054		$ 1,930	6 %		$ 4,112		$ 3,770	9 %

(1) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

The Cigna Group
Evernorth Health Services
Segment Results (unaudited)

(Dollars in millions)	Three Months Ended June 30,			Six Months Ended June 30,		
	2026	2025	% Change	2026	2025	% Change
Revenues						
Pharmacy revenues	$ 57,490	$ 53,989	6 %	$ 111,784	$ 104,215	7 %
Fees and other revenues	3,959	3,805	4	8,082	7,229	12
Net investment income	19	31	(39)	44	62	(29)
Total revenues (1)	61,468	57,825	6	119,910	111,506	8
Benefits and expenses						
Pharmacy and other service costs	58,531	54,939	7	114,231	106,060	8
Selling, general and administrative expenses (2)	1,044	1,074	(3)	2,093	2,098	—
Amortization of acquired intangible assets	387	416	(7)	775	831	(7)
Special items	7	47	(85)	11	68	(84)
Total benefits and expenses	59,969	56,476	6	117,110	109,057	7
Income from operations	1,499	1,349	11	2,800	2,449	14
Interest expense and other	—	1	N/M	(1)	1	N/M
Gain on sale of businesses	—	—	N/M	—	4	N/M
Net investment (losses) gains	(76)	80	N/M	185	84	120
Income before income taxes	1,423	1,430	—	2,984	2,538	18
Pre-tax adjustments required to reconcile to adjusted income from operations						
Pre-tax (income) attributable to noncontrolling interests	(230)	(117)		(456)	(219)	
Net investment losses (gains)	76	(80)		(185)	(84)	
Amortization of acquired intangible assets	387	416		775	831	
Special items	7	47		11	64	
Pre-tax adjusted income from operations	$ 1,663	$ 1,696	(2) %	$ 3,129	$ 3,130	— %
Pre-tax margin	2.7 %	2.9 %	(20) bps	2.6 %	2.8 %	(20) bps

(1) Total revenues equal adjusted revenues as there were no special items in the periods presented.

(2) Selling, general and administrative expenses reflect the expenses included in the evaluation of Evernorth Health Services' performance.

The Cigna Group
Evernorth Health Services
Selected Financial Information (unaudited)

(Dollars and pharmacy scripts in millions)	Three Months Ended June 30,			Six Months Ended June 30,		
	2026	2025	% Change	2026	2025	% Change
Total adjusted revenues						
Pharmacy Benefit Services [1]	$ 34,496	$ 31,954	8 %	$ 67,498	$ 61,696	9 %
Specialty and Care Services [1]	26,972	25,871	4	52,412	49,810	5
Total adjusted revenues	$ 61,468	$ 57,825	6 %	$ 119,910	$ 111,506	8 %
Pre-tax adjusted income from operations						
Pharmacy Benefit Services [1]	$ 609	$ 833	(27) %	$ 1,003	$ 1,377	(27) %
Specialty and Care Services [1]	1,054	863	22	2,126	1,753	21
Total pre-tax adjusted income from operations	$ 1,663	$ 1,696	(2) %	$ 3,129	$ 3,130	— %
Pharmacy claim volume [2]	537	548	(2) %	1,064	1,087	(2) %

(1) Includes Net investment income of $2 million and $17 million for Pharmacy Benefit Services and $17 million and $14 million for Specialty and Care Services for the three months ended June 30, 2026 and 2025, respectively, and $9 million and $33 million for Pharmacy Benefit Services and $35 million and $29 million for Specialty and Care Services for the six months ended June 30, 2026 and 2025, respectively.

(2) Non-specialty network prescriptions filled through 90-day programs and home delivery prescriptions are counted as three claims. All other network and specialty prescriptions are counted as one claim.

The Cigna Group
Cigna Healthcare
Segment Results (unaudited)

(Dollars in millions)	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	% Change	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025	% Change
Revenues						
Premiums	$ 9,656	$ 8,992	7 %	$ 19,261	$ 21,620	(11) %
Fees and other revenues	2,007	1,679	20	3,753	3,450	9
Net investment income	175	127	38	278	260	7
Total revenues	11,838	10,798	10	23,292	25,330	(8)
Benefits and expenses						
Medical costs	8,161	7,482	9	15,825	17,867	(11)
Selling, general and administrative expenses (1)	2,293	2,180	5	4,594	4,992	(8)
Amortization of acquired intangible assets	2	6	(67)	4	13	(69)
Special items	99	10	N/M	101	10	N/M
Total benefits and expenses	10,555	9,678	9	20,524	22,882	(10)
Income from operations	1,283	1,120	15	2,768	2,448	13
Interest expense and other	2	2	—	4	4	—
Gain on sale of businesses	6	—	N/M	6	37	(84)
Net investment gains (losses)	17	(24)	N/M	11	(27)	N/M
Income before income taxes	1,308	1,098	19	2,789	2,462	13
Pre-tax adjustments required to reconcile to adjusted income from operations						
Net investment (gains) (2)	(127)	(20)		(98)	(67)	
Amortization of acquired intangible assets	2	6		4	13	
Special items	93	10		95	(27)	
Pre-tax adjusted income from operations	$ 1,276	$ 1,094	17 %	$ 2,790	$ 2,381	17 %
Pre-tax margin	10.9 %	10.2 %	70 bps	12.0 %	9.4 %	260 bps
Reconciliation of total revenues to adjusted revenues						
Total revenues	$ 11,838	$ 10,798	10 %	$ 23,292	$ 25,330	(8) %
Net investment results from certain equity method investments	(110)	(44)	150	(87)	(94)	(7)
Adjusted revenues	$ 11,728	$ 10,754	9 %	$ 23,205	$ 25,236	(8) %

(1) Selling, general and administrative expenses reflect the expenses included in the assessment of Cigna Healthcare's performance.

(2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

The Cigna Group
Cigna Healthcare
Premium Revenue and Medical Care Ratio (unaudited)

(Dollars in millions)	Three Months Ended June 30,			Six Months Ended June 30,		
	2026	2025	% Change	2026	2025	% Change
Premiums:						
U.S. Healthcare						
Employer insured	$ 4,989	$ 4,684	7 %	$ 9,985	$ 9,372	7 %
Stop loss	2,138	1,879	14	4,254	3,747	14
Individual and Family Plans	860	941	(9)	1,733	1,800	(4)
Other	525	462	14	1,032	919	12
U.S. Healthcare - ongoing businesses	8,512	7,966	7	17,004	15,838	7
Medicare Advantage (1)	—	—	N/M	—	2,363	N/M
Other (1)	—	—	N/M	—	1,415	N/M
U.S. Healthcare - divested businesses (1)	—	—	N/M	—	3,778	N/M
Total U.S. Healthcare	8,512	7,966	7	17,004	19,616	(13)
International Health	1,144	1,026	12	2,257	2,004	13
Total premiums	$ 9,656	$ 8,992	7 %	$ 19,261	$ 21,620	(11) %
Medical Care Ratio	84.5 %	83.2 %	130 bps	82.2 %	82.6 %	(40) bps

(1) On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses (the "HCSC transaction"). For additional information, please refer to the Divestiture footnote in the Company's Form 10-K for the period ended December 31, 2025.

The Cigna Group
Cigna Healthcare
Total Medical Customers (unaudited)

MEDICAL CUSTOMERS [1] BY FUNDING TYPE:	As of June 30, 2026	As of June 30, 2025 [5]	% Change	As of December 31, 2025	% Change
(Lives in thousands)					
U.S. Healthcare insured					
Employer insured	2,107	2,181	(3) %	2,179	(3) %
Individual and Family Plans [2]	332	393	(16)	369	(10)
Total U.S. Healthcare insured	2,439	2,574	(5)	2,548	(4)
International Health insured [3]	1,262	1,250	1	1,260	—
U.S. Healthcare administrative services only	14,239	13,781	3	13,875	3
International Health administrative services only [3]	473	441	7	435	9
Total medical customers	18,413	18,046	2 %	18,118	2 %

MEDICAL CUSTOMERS [1] BY MARKET SEGMENT: [4]	As of June 30, 2026	As of June 30, 2025 [5]	% Change	As of December 31, 2025 [5]	% Change
(Lives in thousands)					
U.S. Healthcare					
National Accounts	5,168	5,440	(5) %	5,415	(5) %
Middle Market	7,902	7,377	7	7,460	6
Select	3,274	3,131	5	3,174	3
Small	2	14	(86)	5	(60)
Individual and Family Plans [2]	332	393	(16)	369	(10)
Total U.S. Healthcare	16,678	16,355	2	16,423	2
International Health	1,735	1,691	3	1,695	2
Total medical customers	18,413	18,046	2 %	18,118	2 %

(1) *Includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care arrangement or administrative services agreement issued by Cigna Healthcare; (ii) have access to the Cigna Healthcare provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna Healthcare.*

(2) *As of June 30, 2026, Individual and Family Plans medical business includes on-exchange Patient Protection and Affordable Care and Education Reconciliation Act (“ACA”) business (319 thousand customers) and off-exchange ACA business (13 thousand customers). In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.*

(3) *International Health excludes medical customers served by less than 100% owned subsidiaries, as well as certain customers served by our third-party administrator.*

(4) *Market Segments are defined as follows:*
~ the National Accounts market segment includes employers with 3,000 or more eligible employees;
~ the Middle Market segment includes employers with 500 to 2,999 eligible employees, solutions for third party payers, Taft Hartley plans, and other groups;
~ the Select market segment includes employers with 51 to 499 eligible employees;
~ the Small market segment includes employers with 2 to 50 eligible employees;
~ the Individual and Family Plans market segment offers individual health insurance coverage both on and off the public exchanges;
~ the International Health market segment is focused on health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations.

(5) *Prior year lives have been reclassified to reflect current market segment presentation according to the definitions discussed in note 4.*

The Cigna Group
Cigna Healthcare
Unpaid Claims Liability (unaudited) [1]

(Dollars in millions)	Six Months Ended June 30,		Year Ended
	2026	2025	December 31, 2025
Beginning balance	$ 4,241	$ 5,018	$ 5,018
Less: Reinsurance and other amounts recoverable	147	159	159
Beginning balance, net	4,094	4,859	4,859
Incurred costs related to:			
Current year	16,093	18,163	33,816
Prior years	(268)	(297)	(342)
Total incurred	15,825	17,866	33,474
Paid costs related to:			
Current year	11,576	13,019	28,769
Prior years	3,258	3,889	4,147
Total paid	14,834	16,908	32,916
Less: Divestiture and other	—	1,323	1,323
Ending balance, net	5,085	4,494	4,094
Add: Reinsurance and other amounts recoverable	143	142	147
Ending balance	$ 5,228	$ 4,636	$ 4,241

(1) Unpaid claims liability is included in the Insurance and contractholder liabilities balance on the Consolidated Balance Sheets, except $983 million classified as liabilities of businesses held for sale as of December 31, 2024. For additional information regarding this liability, see the Insurance and Contractholder Liabilities footnote in the Company's Form 10-Q for the period ended June 30, 2026, expected to be filed on July 30, 2026.

The Cigna Group
Corporate and Other Operations
Results (unaudited)

(Dollars in millions)	Three Months Ended June 30,			Six Months Ended June 30,		
	2026	2025	% Change	2026	2025	% Change
Revenues						
Total revenues and eliminations [(1)]	$ (1,638)	$ (1,445)	13 %	$ (3,040)	$ (4,156)	(27) %
Expenses						
Total expenses and eliminations excluding special items [(1)]	(1,606)	(1,387)	16	(2,975)	(4,034)	(26)
Special items	74	105	(30)	469	498	(6)
Total expenses and eliminations [(1)]	(1,532)	(1,282)	20	(2,506)	(3,536)	(29)
Loss from operations	(106)	(163)	(35)	(534)	(620)	(14)
Interest expense and other	(358)	(340)	5	(716)	(704)	2
Gain on sale of businesses	—	—	N/M	11	—	N/M
Net investment losses	(10)	(4)	150	(7)	(7)	—
Loss before income taxes	(474)	(507)	(7)	(1,246)	(1,331)	(6)
Pre-tax adjustments required to reconcile to adjusted income (loss) from operations						
Net investment losses	10	4		7	7	
Special items	75	146		473	556	
Pre-tax adjusted loss from operations	$ (389)	$ (357)	9 %	$ (766)	$ (768)	— %

(1) Includes amounts for elimination of intercompany revenues and expenses.

The Cigna Group
Consolidated Balance Sheets (unaudited)

(Dollars in millions)	As of June 30, 2026	As of December 31, 2025		As of June 30, 2026	As of December 31, 2025
Assets			**Liabilities**		
Current Assets			**Current Liabilities**		
Cash and cash equivalents	$ 6,298	$ 7,676	Current insurance and contractholder liabilities	$ 6,689	$ 5,710
Investments	959	1,056	Pharmacy and other service costs payable	26,225	30,333
Accounts receivable, net	30,800	28,768	Accounts payable	10,409	10,659
Inventories	5,847	7,338	Accrued expenses and other liabilities	9,447	9,048
Other current assets	3,087	2,976	Short-term debt	2,792	592
Total current assets	46,991	47,814	Total current liabilities	55,562	56,342
Long-term investments	19,037	18,471	Non-current insurance and contractholder liabilities	9,633	9,938
Reinsurance recoverables	3,982	4,103	Deferred tax liabilities, net	6,731	7,145
Property and equipment	3,736	3,651	Other non-current liabilities	5,612	4,238
Goodwill	45,534	44,924	Long-term debt	29,086	30,871
Other intangible assets	26,931	28,560	Separate account liabilities	7,548	7,511
Other assets	3,323	2,885	Total liabilities	114,172	116,045
Separate account assets	7,548	7,511			
			Shareholders’ Equity		
			Common stock	4	4
			Additional paid-in capital	32,092	31,790
			Accumulated other comprehensive loss	(4,361)	(2,806)
			Retained earnings	50,355	47,865
			Less: Treasury stock, at cost	(35,470)	(35,140)
			Total shareholders' equity	42,620	41,713
			Noncontrolling interests	290	161
			Total equity	42,910	41,874
Total assets	$ 157,082	$ 157,919	Total liabilities and equity	$ 157,082	$ 157,919

The Cigna Group
Condensed Consolidated Statements of Cash Flows (unaudited)

(Dollars in millions)	Six Months Ended June 30,	
	2026	2025
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	$ 3,736	$ 3,041
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	1,305	1,356
Investment gains, net	(189)	(50)
Deferred income tax benefit	(170)	(292)
Gain on sale of businesses	(17)	(41)
Net changes in assets and liabilities, net of non-operating effects:		
Accounts receivable, net	(2,044)	(6,398)
Inventories	1,490	726
Reinsurance recoverable and Other assets	(398)	(402)
Insurance liabilities	906	1,702
Pharmacy and other service costs payable	(4,108)	995
Accounts payable and accrued expenses and other liabilities	230	(1,020)
Other, net	(31)	417
Net cash provided by operating activities	710	34
Net cash (used in) provided by investing activities	(1,140)	400
Net cash used in financing activities	(934)	(5,014)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash	(16)	35
Net decrease in cash, cash equivalents and restricted cash	(1,380)	(4,545)
Cash, cash equivalents and restricted cash January 1, (1)	7,736	8,931
Cash, cash equivalents and restricted cash June 30, (2)	$ 6,356	$ 4,386

(1) Includes restricted cash of $60 million reported in other long-term investments and Other assets as of January 1, 2026.

(2) Includes restricted cash of $58 million reported in other long-term investments and Other assets as of June 30, 2026.